Tenax Therapeutics appoints Thomas R. Staab, II as CFO effective May 11, 2026

TENAX THERAPEUTICS, INC.

Staab, a 25-year healthcare finance veteran, most recently CFO of LENSAR (LNSR) until May 2026.
Base salary of $428,000 with 45% target bonus; inducement equity of 10,000 RSUs and 450,000 option shares.
Interim CFO Thomas McGauley resigns May 10, 2026 but will stay through filing of Q1 10-Q and provide consulting transition.
Staab's RSUs vest 25% after 10 days, remainder quarterly; options vest 25% after 1 year then monthly over 3 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.